• Advertise
  • Contact Us
  • About Us
  • Supplier Directory
  • SCB YouTube
  • Login
  • Subscribe
  • Logout
  • My Profile

  • CORONAVIRUS
  • LOGISTICS
    • Air Cargo
    • All Logistics
    • Express/Small Shipments
    • Facility Location Planning
    • Freight Forwarding/Customs Brokerage
    • Global Gateways
    • Global Logistics
    • Last Mile Delivery
    • Logistics Outsourcing
    • LTL/Truckload Services
    • Ocean Transportation
    • Rail & Intermodal
    • Reverse Logistics
    • Service Parts Management
    • Transportation & Distribution
  • TECHNOLOGY
    • All Technology
    • Artificial Intelligence
    • Cloud & On-Demand Systems
    • Data Management (Big Data/IoT/Blockchain)
    • ERP & Enterprise Systems
    • Forecasting & Demand Planning
    • Global Trade Management
    • Inventory Planning/ Optimization
    • Product Lifecycle Management
    • Sales & Operations Planning
    • SC Finance & Revenue Management
    • SC Planning & Optimization
    • Sourcing/Procurement/SRM
    • Supply Chain Visibility
    • Transportation Management
  • GENERAL SCM
    • Business Strategy Alignment
    • Education & Professional Development
    • Global Supply Chain Management
    • Global Trade & Economics
    • HR & Labor Management
    • Quality & Metrics
    • Regulation & Compliance
    • SC Security & Risk Mgmt
    • Supply Chains in Crisis
    • Sustainability & Corporate Social Responsibility
  • WAREHOUSING
    • All Warehouse Services
    • Conveyors & Sortation
    • Lift Trucks & AGVs
    • Order Fulfillment
    • Packaging
    • RFID, Barcode, Mobility & Voice
    • Robotics
    • Warehouse Management Systems
  • INDUSTRIES
    • Aerospace & Defense
    • Apparel
    • Automotive
    • Chemicals & Energy
    • Consumer Packaged Goods
    • E-Commerce/Omni-Channel
    • Food & Beverage
    • Healthcare
    • High-Tech/Electronics
    • Industrial Manufacturing
    • Pharmaceutical/Biotech
    • Retail
  • REGIONS
    • Asia Pacific
    • Canada
    • China
    • Europe
    • Latin America
    • Middle East/Africa
    • North America
  • THINK TANK
  • WEBINARS
    • On-Demand Webinars
    • Upcoming Webinars
  • PODCASTS
  • VIDEOS
  • WHITEPAPERS
Home » Carcinogen in Zantac and Generics Triggers FDA, EU Probes

Carcinogen in Zantac and Generics Triggers FDA, EU Probes

Carcinogen in Zantac and Generics Triggers FDA, EU Probes
September 17, 2019
Bloomberg

Global health regulators sounded a coordinated alarm about the possibility that a stomach drug taken by millions of people could be tainted with the same cancer-causing agent that has sparked a worldwide recall of blood-pressure pills.

Drug-safety officials in the U.S. and Europe said Friday that they were looking into whether Sanofi heartburn medication Zantac and generic versions made by numerous manufacturers contain levels of the probable carcinogen NDMA that could pose a danger to patients.

Ranitidine, as the drug is known in generic form, is an antacid and antihistamine used to treat and prevent a range of gastrointestinal disorders. The chemical NDMA, or N-Nitrosodimethylamine, is a likely human carcinogen found in cooked or cured meats such as bacon, and is a common industrial byproduct.

The discovery further underscores the challenge pharmaceutical-industry regulators face in overseeing a vast global supply chain of drugs, drug ingredients and factory processes. Dozens of versions of the hypertension treatment valsartan have been recalled since last year out of concern they could be contaminated with NDMA.

Many of those drugs were made in China or India, raising questions about the quality of generic manufacturing in far-flung factories around the globe. Bloomberg News has reported on how poor quality controls and efforts to conceal manufacturing problems from the FDA have complicated oversight of overseas drug producers.

“Sanofi takes patient safety seriously, and we are committed to working with the FDA,” Ashleigh Koss, a spokeswoman for the company, said in an email. Zantac is made in Mexico and Sanofi sources its active ingredient from Spain, Koss said.

The review of ranitidine comes after Valisure, a New Haven, Connecticut-based online pharmacy that tests all the medications it dispenses, alerted the U.S. Food and Drug Administration that it had detected high levels of NDMA in both generic and brand versions of Zantac sold at major pharmacies run by companies including Walgreens Boots Alliance Inc., CVS Health Corp. and Walmart Inc.

The FDA said in a statement Friday it would review branded and generic versions of the medication. The European Medicines Agency said it “is evaluating the data to assess whether patients using ranitidine are at any risk from NDMA and will provide information about this as soon as it is available.”

The FDA detected NDMA in both prescription and over-the-counter versions of Zantac but hasn’t collected enough samples to give a range of carcinogen levels found, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, said in an interview. FDA and European regulators use different testing methods than Valisure, she said, but declined to give details.

Valisure filed a petition with the FDA on Friday asking the agency to recall Zantac and its generics that contain NDMA. The FDA said the NDMA levels in the drugs are low, while Valisure’s petition called them excessive.

“We don’t think this poses an immediate hazard to human health so we’ll have an ongoing process to determine whether recalls are needed,” Woodcock said.

Inherently Present

The FDA didn’t recommend people who take Zantac or its generics stop taking it but advised that other medications are available.

Once international regulators agree on NDMA testing methods for the drugs, the agency will ask manufacturers to test their versions of Zantac, Woodcock said. The agency will also seek samples from manufacturers to test itself and expects it will take a couple weeks to get more information, Woodcock said.

The FDA doesn’t know how NDMA got into the drugs but its preliminary hypothesis is that it is different from the manufacturing process for the blood-pressure pills that are also tainted, agency spokesman Jeremy Kahn said in an email.

Valisure Chief Executive Officer David Light said his company thinks NDMA is inherently present in Zantac. A Stanford University study was done in 2016 based on a similar understanding.

Stanford environmental researchers interested in how NDMA forms at low levels in wastewater measured levels of the carcinogen in the urine of 10 volunteers who took ranitidine. They found that NDMA levels rose 400-fold after volunteers took the drug, to 48 micrograms — nearly triple the 17 micrograms the FDA found in some recalled blood-pressure pills.

The scientists said in their research that the risks of ranitidine should be evaluated.

“We’re not in that field so we basically left it at that,” William Mitch, one of the Stanford researchers, said in an interview. “We put it out as food for thought hoping someone would pick it up.”

Research Effort

Researchers at the Memorial Sloan Kettering Cancer Center are also looking into whether NDMA levels in generic and brand-name Zantac may be linked to an increased risk of cancer based on the findings shared by Valisure, said Lior Braunstein, an oncologist at Sloan Kettering who is co-leading the research on Zantac.

Zantac and its generics are sold with and without a prescription in different strengths. Almost 25 million prescriptions for the drugs were written in 2018, according to Bloomberg Intelligence data.

“There’s no acceptable cancer risk for a drug like this,” Valisure CEO Light said.

Zantac isn’t just taken by adults. It is also given to infants suffering from reflux in a syrup form that requires a prescription.

The FDA found NDMA levels as high as 17 micrograms in blood-pressure pills recalled starting in July 2018. Valisure detected NDMA levels as high as 3,000 micrograms in Zantac pills and its generics. In the wake of recalls of blood-pressure drugs, the FDA set an NDMA limit of less than one microgram for the pills and required all companies that make the hypertension treatments to test for the contaminant.

RELATED CONTENT

RELATED VIDEOS

Sourcing/Procurement/SRM Supply Chain Visibility Global Supply Chain Management Quality & Metrics Regulation & Compliance Supply Chain Security & Risk Mgmt Healthcare Pharmaceutical/Biotech Asia Pacific China Europe North America
KEYWORDS Asia Pacific China Europe healthcare North America Pharmaceutical/Biotech Quality & Metrics Regulation & Compliance SC Security & Risk Mgmt Sourcing/Procurement/SRM Supply Chain Visibility
  • Related Articles

    Major U.S. Drugstore Chains Pull Zantac Amid Carcinogen Concern

    EU Probes Tax Schemes of Major Corporations Active in Europe

Bloomberg

CVS, Rite Aid Ration Contraceptive Pills as Demand Surges

More from this author

Wake up to live
“Supply Chains in Crisis”
updates and the latest Supply Chain News!

Subscribe to our Daily Newsletter

Timely, incisive articles delivered directly to your inbox.

Popular Stories

  • coworkers collaborate

    Podcast | Linking Planning and Execution for Real-Time Decision-Making

    Sales & Operations Planning
  • FedEx

    FedEx Faces Big Changes as New Boss Confronts Higher Costs, Angry Contractors

    Last Mile Delivery
  • 0621_Burrito.png

    Chipotle Zeroes in on Supply Chain Traceability and Visibility

    Sourcing/Procurement/SRM
  • cyber crime

    The Cyber Blind Spot That Makes Every Supply Chain Vulnerable

    Regulation & Compliance
  • 0627_Guitars.png

    Sweetwater Responds to the ‘New Face of Agility’ in Supply Chain and Merchandising

    Inventory Planning/ Optimization

Digital Edition

Scb may 2022 sm

2022 Supply Chain ESG Guide

VIEW THE LATEST ISSUE

Case Studies

  • 3PL Doubles Productivity With Robots to Fulfill Medical Supply Orders

  • E-Commerce Company Cuts Order Fulfillment Time by 40%

  • Fashion Retailer Halves Fulfillment Time With Omichannel Automation

  • Distributor Scales Business by Integrating Warehouse Automaton Software

  • Fast-Growing Fashion Brand Scales E-Commerce Fulfillment With Whiplash

Visit Our Sponsors

Yang Ming Alithya Barcoding
Blue Yonder BNSF Logistics Generix
GEP GreyOrange Here
Honeywell Intelligrated IFM Inmar
Keelvar Kinaxis Korber
Liberty SBF Locus Robotics Logility
Lucas Systems Nvidia Old Dominion
ORTEC Parsyl QIMA
Redwood Logistics Saddle Creek Logistics Schneider Dedicated
Setlog Holding AG Ship4WD Shipwell
Tecsys TGW Systems Thomson Reuters
Tive Trailer Bridge Vecna Robotics
Verity
  • More From SCB
    • Featured Content
    • Video Library
    • Think Tank Blog
    • SupplyChainBrain Podcast
    • Whitepapers
    • On-Demand Webinars
    • Upcoming Webinars
  • Digital Offerings
    • Digital Issue
    • Subscribe
    • Manage Your Subscription
    • Newsletters
  • Resources
    • Events Calendar
    • SCB's Great Supply Chain Partners
    • Supplier Directory
    • Case Study Showcase
    • Supply Chain Innovation Awards
    • 100 Great Partners Form
  • SCB Corporate
    • Advertise on SCB.COM
    • About Us
    • Privacy Policy
    • Contact Us
    • Data Sharing Opt-Out

All content copyright ©2022 Keller International Publishing Corp All rights reserved. No reproduction, transmission or display is permitted without the written permissions of Keller International Publishing Corp

Design, CMS, Hosting & Web Development :: ePublishing